Eli Lilly's Experimental Obesity Drug Achieves Over 11% Weight Loss in Early Trials
Eli Lilly's experimental obesity drug, eloralintide, showed promising results in early trials, with some patients losing over 11% of their body weight in 12 weeks, and the drug appears to be safe and effective, potentially serving as a successor or complement to existing obesity treatments like tirzepatide.